Open an account

NovaBridge Biosciences

NBP · NASDAQ

$1.43−$0.005 (−0.35%)TodayMarket closed ·
Prev close $1.43

NBP analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy1
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 5 analysts

Average $8.93 (+526.3% upside)

Low
$8.08
Now
$1.43
High
$9.45

Upgrades and downgrades

The latest rating actions, newest first

NBP analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Aug 20, 2026MaintainsBuy
HC Wainwright & Co.Apr 8, 2026MaintainsBuy
HC Wainwright & Co.Mar 16, 2026MaintainsBuy
HC Wainwright & Co.Feb 6, 2026MaintainsBuy

The case for and against

Updated Sep 26, 2026

Bull case

NovaBridge Biosciences is a promising company with a positive outlook due to its diverse pipeline of innovative immunotherapy drugs, including its lead asset givastomig, a potential treatment for gastric cancer and other gastrointestinal malignancies. The company's recent updates on givastomig and VIS-101 demonstrate their potential to become differentiated assets in the anti-VEGF market through their clinical durability and unique mechanism of action. The company's "hub-and-spoke" business model and ongoing development efforts only add to its potential upside and reinforce our confidence in its long-term success.

Bear case

NovaBridge Biosciences is experiencing financial struggles due to a net loss of $37.9M and negative cash flow from operating activities of $32.9M in the first half of 2026. Additionally, their main product, givastomig, may face challenges as it competes with similar anti-VEGF drugs and the company will need to closely monitor updates and efficacy of their drugs in larger trials. Furthermore, research efforts should focus on refining assumptions around market capture and examining the correlation between early gastritis and givastomig's efficacy.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.